409 related articles for article (PubMed ID: 25939673)
1. Statin-associated ocular disorders: the FDA and ADRAC data.
Mizranita V; Pratisto EH
Int J Clin Pharm; 2015 Oct; 37(5):844-50. PubMed ID: 25939673
[TBL] [Abstract][Full Text] [Related]
2. Diplopia, blepharoptosis, and ophthalmoplegia and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor use.
Fraunfelder FW; Richards AB
Ophthalmology; 2008 Dec; 115(12):2282-5. PubMed ID: 18930555
[TBL] [Abstract][Full Text] [Related]
3. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
Chang JT; Staffa JA; Parks M; Green L
Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
[TBL] [Abstract][Full Text] [Related]
4. Statin adverse effects: patients' experiences and laboratory monitoring of muscle and liver injuries.
Chaipichit N; Krska J; Pratipanawatr T; Jarernsiripornkul N
Int J Clin Pharm; 2015 Apr; 37(2):355-64. PubMed ID: 25630895
[TBL] [Abstract][Full Text] [Related]
5. Effect of statins on blood pressure: Analysis on adverse events released by FDA.
You T; Liu XG; Hou XD; Wang XK; Xie HH; Ding F; Yi K; Zhang P; Xie XD
Clin Exp Hypertens; 2017; 39(4):325-329. PubMed ID: 28513233
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Statin-Associated Myopathy Case Reports in Thailand Using the Health Product Vigilance Center Database.
Boonmuang P; Nathisuwan S; Chaiyakunapruk N; Suwankesawong W; Pokhagul P; Teerawattanapong N; Supsongserm P
Drug Saf; 2013 Sep; 36(9):779-87. PubMed ID: 23615756
[TBL] [Abstract][Full Text] [Related]
7. Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis.
McAdams M; Staffa J; Dal Pan G
Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):229-39. PubMed ID: 18175291
[TBL] [Abstract][Full Text] [Related]
8. Statin safety: an assessment using an administrative claims database.
Cziraky MJ; Willey VJ; McKenney JM; Kamat SA; Fisher MD; Guyton JR; Jacobson TA; Davidson MH
Am J Cardiol; 2006 Apr; 97(8A):61C-68C. PubMed ID: 16581331
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system.
Colman E; Szarfman A; Wyeth J; Mosholder A; Jillapalli D; Levine J; Avigan M
Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1068-76. PubMed ID: 18821724
[TBL] [Abstract][Full Text] [Related]
10. Fluvastatin and hepatic reactions: a signal from spontaneous reporting in Italy.
Conforti A; Magro L; Moretti U; Scotto S; Motola D; Salvo F; Ros B; Leone R
Drug Saf; 2006; 29(12):1163-72. PubMed ID: 17147462
[TBL] [Abstract][Full Text] [Related]
11. Statin-associated psychiatric adverse events: a case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting.
Tuccori M; Lapi F; Testi A; Coli D; Moretti U; Vannacci A; Motola D; Salvo F; Rivolta AL; Blandizzi C; Mugelli A; Del Tacca M
Drug Saf; 2008; 31(12):1115-23. PubMed ID: 19026028
[TBL] [Abstract][Full Text] [Related]
12. Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).
Alsheikh-Ali AA; Karas RH
Am J Cardiol; 2007 Feb; 99(3):379-81. PubMed ID: 17261402
[TBL] [Abstract][Full Text] [Related]
13. Use of multiple international healthcare databases for the detection of rare drug-associated outcomes: a pharmacoepidemiological programme comparing rosuvastatin with other marketed statins.
García Rodríguez LA; Herings R; Johansson S
Pharmacoepidemiol Drug Saf; 2010 Dec; 19(12):1218-24. PubMed ID: 20922707
[TBL] [Abstract][Full Text] [Related]
14. Statin safety: lessons from new drug applications for marketed statins.
Jacobson TA
Am J Cardiol; 2006 Apr; 97(8A):44C-51C. PubMed ID: 16581328
[TBL] [Abstract][Full Text] [Related]
15. Onset timing of statin-induced musculoskeletal adverse events and concomitant drug-associated shift in onset timing of MAEs.
Akimoto H; Negishi A; Oshima S; Okita M; Numajiri S; Inoue N; Ohshima S; Kobayashi D
Pharmacol Res Perspect; 2018 Dec; 6(6):e00439. PubMed ID: 30443347
[TBL] [Abstract][Full Text] [Related]
16. Examining the Nocebo Effect of Statins Through Statin Adverse Events Reported in the Food and Drug Administration Adverse Event Reporting System.
Moon J; Cohen Sedgh R; Jackevicius CA
Circ Cardiovasc Qual Outcomes; 2021 Jan; 14(1):e007480. PubMed ID: 33161769
[TBL] [Abstract][Full Text] [Related]
17. Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports.
Fernández AB; Karas RH; Alsheikh-Ali AA; Thompson PD
Chest; 2008 Oct; 134(4):824-830. PubMed ID: 18689579
[TBL] [Abstract][Full Text] [Related]
18. Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug-drug interactions through the FDA adverse event reporting system.
Antonazzo IC; Poluzzi E; Forcesi E; Salvo F; Pariente A; Marchesini G; De Ponti F; Raschi E
Acta Diabetol; 2020 Jan; 57(1):71-80. PubMed ID: 31203438
[TBL] [Abstract][Full Text] [Related]
19. Statin-associated myopathy.
Thompson PD; Clarkson P; Karas RH
JAMA; 2003 Apr; 289(13):1681-90. PubMed ID: 12672737
[TBL] [Abstract][Full Text] [Related]
20. Statin-associated lower urinary tract symptoms: data mining of the public version of the FDA adverse event reporting system, FAERS.
Fujimoto M; Hosomi K; Takada M
Int J Clin Pharmacol Ther; 2014 Apr; 52(4):259-66. PubMed ID: 24472404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
